Hungarian pharmaceutical company HYD Pharma has just completed a HUF 250 mln research phase in the development of a new drug for cancer patients, Hungarian news agency MTI reported today. The company’s research and development unit has succeeded in producing a drug which contains deuterium-depleted water or DDW.
Deuterium-depletet water is known to mitigate the damaging effects of chemotherapy and radiation such as nausea, pain or hair loss.
The company will now proceed with clinical tests, the cost of which could reach a nine-figure range, HYD Pharma’s CEO said.
Venture capital fund manager Primus Capital recently invested HUF 400 mln in the pharmaceutical company. HYD Pharma’s net revenue totalled HUF 693 mln in 2013.